Retevmo 80mg Capsule

Retevmo 80mg capsule is a prescription based anticancer medication. The medication active ingredient is Selpercatinib which belongs to the drug class of tyrosine kinase inhibitor. It blocking abnormal RET proteins that promote the growth and spread of cancer cells, helping to slow down or stop tumor progression.

The medication is used to treat RET positive non small cell lung cancer (NSCLC), Medullary thyroid cancer and other RET driven tumors. Taking the dose exactly as prescribed by the healthcare professional.

• Treats non small cell lung cancer, thyroid cancer and certain other solid tumors.
  

Every medication has several side effects. Retevmo 80mg capsule also causes various symptoms, many of them are resolve on their own and some need proper medical attention. Common ones include:

• Swelling
• Diarrhea
• Fatigue
• Dryness
• Fever
• Abdominal pain
• Dizziness
• Weakness​

• Dosage and duration is correctly administered by the healthcare professional to ensure the medication is effective and lower the risk of side effects on patients. Retevmo 80mg capsule should be taken with or without food at the fixed time everyday to enhance the effectiveness of the treatment.
• Do not miss or skip the dose without consultation with a healthcare professional as it may reduce the benefit of the treatment and allow the cancer to progress or become less responsive to the therapy.
  

• Retevmo 80mg capsule works by blocking the RET ( rearranged during transfection) tyrosine kinase, which is abnormality activated in certain cancers due to RET gene fusion or mutation. By inhibiting RET growth signaling Retevmo 80mg slows or stop the growth of cancer cells in the body.
• The medicine also prevents the body from multiplication or spreading tumor to the other body parts.
  

• Markham, A. (2020). Selpercatinib: first approval. Drugs, 80(11), 1119-1124. https://pubmed.ncbi.nlm.nih.gov/32557397/
• Drilon, A., Oxnard, G. R., Tan, D. S., Loong, H. H., Johnson, M., Gainor, J., ... & Subbiah, V. (2020). Efficacy of selpercatinib in RET fusion–positive non–small-cell lung cancer. New England Journal of Medicine, 383(9), 813-824. https://pubmed.ncbi.nlm.nih.gov/32846060/
• Bradford, D., Larkins, E., Mushti, S. L., Rodriguez, L., Skinner, A. M., Helms, W. S., ... & Singh, H. (2021). FDA approval summary: selpercatinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions. Clinical Cancer Research, 27(8), 2130-2135. https://pubmed.ncbi.nlm.nih.gov/33239432/
• Zhou, C., Solomon, B., Loong, H. H., Park, K., Pérol, M., Arriola, E., ... & Goto, K. (2023). First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion–positive NSCLC. New England Journal of Medicine, 389(20), 1839-1850. https://pubmed.ncbi.nlm.nih.gov/37870973/
• Drilon, A., Subbiah, V., Gautschi, O., Tomasini, P., De Braud, F., Solomon, B. J., ... & Besse, B. (2023). Selpercatinib in patients with RET fusion–positive non–small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I/II trial. Journal of Clinical Oncology, 41(2), 385-394. https://pubmed.ncbi.nlm.nih.gov/36122315/​